3B BlackBio Dx reported a consolidated revenue of approximately INR142 crores with a Profit After Tax (PAT) of nearly INR60 crores for the financial year ended March 31, 2026. The company’s performance was driven by healthy growth in its diagnostic business and strong contributions from its subsidiaries, TRUPCR Europe and Coris BioConcept. Management has provided a revenue growth guidance of 15% to 20% for the upcoming financial year FY27.

The molecular diagnostic business in India grew by approximately 10%, recording sales of INR86.47 crores compared to INR78.34 crores in the previous year. This growth was attributed to increased penetration in government and private laboratories and an expanded distribution network. TRUPCR Europe achieved sales of GBP1.75 million, translating to INR20.67 crores, reflecting a consistent growth trajectory with a CAGR of approximately 40% over the last four years.

Coris BioConcept, acquired in August 2025, contributed consolidated sales of INR35.91 crores for the seven months post-acquisition, along with a PAT of INR8.76 crores. The company is currently focused on the US FDA submission process for selected Antimicrobial Resistance (AMR) products, which management believes will provide access to the significant US diagnostic market. Additionally, the Group is progressing with its In Vitro Diagnostic Regulation (IVDR) transition, having appointed BSI as its notified body and completed QMS audits.

Financial Performance

Looking ahead, the company aims to expand its global presence by strengthening distributor partnerships and entering new geographies across Europe, Africa, Asia Pacific, and Latin America. Management indicated that while domestic growth is expected to be around 15%, international operations are projected to grow between 20% and 25%. The company also maintains a strong cash position, with reserves being actively managed for potential mergers and acquisitions to support long-term expansion.

3B BlackBio Dx Limited reported a consolidated net profit of ₹5992.98 lakh for the financial year ended March 31, 2026, an increase of 25.7% from ₹4769.11 lakh in the previous year. Revenue from operations for the year rose 47.1% to ₹14191.81 lakh from ₹9646.86 lakh in FY25. The Board of Directors recommended a final dividend of ₹5.00 per equity share, subject to shareholder approval at the ensuing Annual General Meeting. The company's Molecular Diagnostics (MDx) division closed the year with revenue of ₹13111.81 lakh, while the Agro-Chemical division recorded export sales of ₹277.74 lakh.

Quarterly Performance

For the quarter ended March 31, 2026, the company recorded a consolidated net profit of ₹980.48 lakh, compared to ₹803.55 lakh in the corresponding quarter of the previous year. Revenue from operations for Q4 stood at ₹3543.41 lakh. On a standalone basis, Q4 net profit came in at ₹744.65 lakh versus ₹924.39 lakh in the same quarter of the previous year, while Q4 standalone revenue stood at ₹2463.01 lakh compared to ₹2301.97 lakh year-on-year.

The company's Q4 EBITDA improved to ₹1464.62 lakh from ₹1253.91 lakh year-on-year. The following table summarises the key quarterly metrics:

Consolidated Financial Results (FY26)

The standalone net profit for the full year was ₹4931.69 lakh, while revenue from operations was ₹9727.50 lakh. The Board, in its meeting held on May 29, 2026, approved the audited standalone and consolidated financial results. Baheti & Company, Statutory Auditors, issued an unmodified opinion on the financial results. The Board also appointed M/s Ali Jain & Sharma, Chartered Accountants, as the Internal Auditor for the financial year 2026-27.

The full-year consolidated financial highlights are presented below:

Segment Performance and Outlook

The Molecular Diagnostics division, contributing the majority of sales, reported revenue of ₹13111.81 lakh for FY26. The division holds approximately 15% market share in the Indian Molecular Diagnostics market, estimated at ₹500–600 Cr. The company expects the MDx industry to grow at 8%–10% CAGR and targets a growth of 15%–20% for FY 2026–27.

The Agro-Chemical division maintained focus on government procurement and exports. Export sales for the division amounted to ₹277.74 lakh in 2025-26 compared to ₹356.75 lakh in 2024-25, a de-growth of 22% attributed to geopolitical tensions in Bangladesh. The division operates with minimal debt and focuses on supplying to existing customers and government tenders.

Notable Developments

Other expenses for the year included one-time fees of ₹174.08 lakh for M&A advisory and due diligence related to the acquisition of Coris Bioconcept SRL, Belgium. The decline in other income was attributed to lower net asset values of debt mutual funds consequent to moderation in interest rates. The company has successfully passed its IVDR-aligned QMS audits conducted by BSI Group in November 2025, with technical evaluation of product groups underway.